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Abstract
Introduction: Rosa26 is a genomic mouse locus commonly used to knock-in cDNA constructs
for ubiquitous or conditional gene expression in transgenic mice. However, the vectors generally
used to generate Rosa26 knock-in constructs show instability problems, which have a severe
impact on the efficiency of the system.
Results: We have optimized the cloning procedure to generate targeting vectors for Cre-
regulated expression of constructs within several days with minimal hands-on time, thereby
enabling high-throughput approaches. We demonstrate that transient expression of Cre still
results in expression of the construct, as shown by the expression level and via functional assays.
In addition to its well-established possibilities in expressing cDNA constructs, we show that the
Rosa26 locus can be used to drive expression of functional miRNA constructs from its endogenous
promoter.
Conclusion: We provide a new high-efficiency cloning system for Rosa26 knock-in constructs to
express either cDNA or miRNA fragments. Our system will enable high-throughput approaches
for controlled expression of cDNA or miRNA constructs, with the latter providing a potential
high-speed alternative for conditional knock-out models.
Introduction
Over recent decades, genetically manipulated mouse
models have proven themselves as valuable tools to study
human disease, both as means to identify and validate
new therapeutic intervention schemes and as models to
study disease mechanisms. Broadly speaking, the genetics
of human diseases can be divided into situations where
the activity of a gene is ectopically activated or increased,
or its endogenous activity is decreased or completely lost.
Therefore, different types of mouse models mimicking
these distinct situations are needed.
For ectopic expression of cDNA constructs in transgenic
mice, the most commonly used method is zygotic pronu-
clear microinjection of complete expression cassettes con-
sisting of enhancer and minimal promoter fragments, the
cDNA of interest, a poly-A signal and sometimes an intron
to enhance expression. However, the random integration
Published: 3 November 2008
PathoGenetics 2008, 1:3 doi:10.1186/1755-8417-1-3
Received: 9 June 2008
Accepted: 3 November 2008
This article is available from: http://www.pathogenetics.com/content/1/1/3
© 2008 Hohenstein et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.PathoGenetics 2008, 1:3 http://www.pathogenetics.com/content/1/1/3
Page 2 of 10
(page number not for citation purposes)
of these constructs into the mouse genome causes much
variability, due to copy number differences and position
effects caused by the site of integration. As a result, differ-
ent independent founder lines need to be tested and the
usefulness of a model cannot be predicted. Even if a useful
model to express a given cDNA in a desired tissue-specific
pattern has been described, using the same regulatory ele-
ments does not guarantee that a different cDNA can be
driven in a comparable manner. In addition, the random
copy number of the integrated construct can result in arti-
ficially high expression levels. In some situations this is an
advantage, but when attempting to mimic the situation
found in human patients as closely as possible, this can be
a severe problem.
An alternative approach is a knock-in of the cDNA of
interest into a well-defined genomic locus using embry-
onic stem (ES) cell targetings followed by injection of cor-
rectly targeted ES cells into blastocysts, the generation of
chimeric mice and germline transmission. The disadvan-
tages of this approach are the more complex vector con-
struction, the need for the identification of correctly
targeted clones and the introduction of an extra genera-
tion of chimeric mice before the experimental mice are
available. However, this is partially compensated for by a
predictable expression pattern. More efficient ways to gen-
erate knock-in vectors for targeting into defined loci with
high targeting efficiency would compensate for the loss in
time resulting from the extra chimeric generation, if fewer
independent mouse lines, or just a single line, would need
to be analysed.
Conventional or conditional gene targeting are the most
widely used methods of inactivating an endogenous gene.
Whereas conventional targeting will only show the earli-
est (lethal) phenotype resulting from a mutation, condi-
tional targeting allows tissue-specific and/or inducible
inactivation of a gene into which loxP recombination sites
have been introduced by controlling the expression of the
Cre recombinase. This method can be very efficient, but
the targeting vector can be complicated to make and tar-
geting efficiencies can differ between loci. In addition, the
effect of targeting an endogenous gene will in most cases
be recessive, leading to additional breeding steps to gener-
ate the experimental mice.
In the last few years the use of siRNA in mammalian sys-
tems has been described as an in vivo alternative to target-
ing of endogenous genes [1], and Cre-regulated systems
have been described for use in mouse models [2]. A major
advantage of this technique is that expression of an RNAi
construct is dominant, and would therefore reduce the
breeding steps to generate experimental mice. A potential
drawback is the fact that knock-down of a gene will gener-
ally not give a 100% loss of gene activity. However, as
genetic aberrations found in patients are often hypomor-
phic mutations this could be considered an advantage,
especially when attempting to mimic a human disease sit-
uation as closely as possible. In fact, an allelic series of dif-
ferent models for a given gene can provide valuable
information on the role of a gene in a disease process [3].
Unfortunately, to achieve the efficiency needed for these
types of experiments, most in vivo RNAi systems described
make use of lentiviral vectors making them impractical for
many laboratories.
The Rosa26 locus was originally identified in a gene-trap
screen in murine ES cells, and was subsequently shown to
be ubiquitously expressed during embryonic develop-
ment and in adult mice [4,5]. The locus is believed to
encode three non-coding transcripts of unknown func-
tion. In the original gene-trap line, the insertion of a splice
acceptor site and promoter-less -geo cDNA in intron 1 of
the gene leads to coupling of its expression to the endog-
enous Rosa26 promoter. Although two of the three tran-
scripts are disrupted, mice homozygous for this insertion
are viable and apparently normal [5]. Subsequently it was
shown that insertion of a lox-STOP-lox cassette between
the splice acceptor site and cDNA places the expression of
the cloned fragment under the control of Cre recombi-
nase, as found in a commonly used transgenic Cre
reporter mouse line [6]. Vectors designed to target the
Rosa26 locus can be targeted with high efficiency (~25%
is normal), making it a locus of choice for targeted knock-
in mouse models.
Srinivas et al [7] described the pBigT vector, which pro-
vided a multiple cloning site and a two-step cloning pro-
cedure for Rosa26 knock-in vectors. Although potentially
powerful, in practice its use can be severely complicated
by an inherent instability of the Rosa26 backbone vector.
In an attempt to streamline the generation of Cre-regu-
lated Rosa26 targeting constructs we adapted the pBigT
vector system to the Gateway cloning system, in which a
combination of att-mediated in vitro recombination and
strong negative counter-selection provides an efficient
DNA shuttling system that can easily be used in high-
throughput cloning projects [8]. Here we describe the use
of this vector to generate both cDNA and miRNA con-
structs with minimal hands-on time.
Results
Generation and use of the pRosa26-DEST vector
To improve the efficiency with which Rosa26 knock-in
vectors can be generated, we first adapted the pBigT vector
[7] to the Gateway cloning system by inserting a Gateway
entry cassette into the multiple cloning site of pBigT. Next,
the splice acceptor-lox-STOP-lox-Gateway entry-poly-A
cassette was subcloned into the Rosa26 backbone as for
normal pBigT vectors to generate pRosa26-DEST. UsingPathoGenetics 2008, 1:3 http://www.pathogenetics.com/content/1/1/3
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this vector, the insert from any Gateway-compatible Entry
vector can be recombined into the final targeting vector in
a single step (Figure 1). When generating knock-in con-
structs using pRosa26-DEST, we found it only took four
days to generate the targeting vectors and have the DNA
ready for targeting. These four days include the Gateway
recombination reaction, transformation into Escherichia
coli, testing several clones by miniprep and performing a
maxiprep of a correct clone to isolate sufficient plasmid
DNA for linearization and electroporation into ES cells.
Most, if not all of these steps can easily be adapted to high-
throughput approaches. In contrast to the pBigT cloning
system, we have found that instability of the vector is not
a limiting problem. We routinely find between 3 and 16
correct colonies when testing 16 E. coli colonies per con-
struct (based on 10 cDNA constructs, data not shown).
The efficiency of the cloning system has been confirmed
in several collaborating laboratories (data not shown).
Use of pRosa26-DEST for Cre-regulated expression of 
cDNA constructs
As a proof of principle, we used pRosa26-DEST to express
a mutant -catenin cDNA under control of Cre. Activating
mutations in the -catenin proto-oncogene are found in a
variety of human tumours and differences in -catenin
activity have been found to lead to different phenotypes
[9], suggesting that physiologically relevant expression
levels are important when modelling human diseases
linked to -catenin mutations in mice. We generated a
Rosa26 knock-in vector carrying a myc-tagged S33Y
mutant form of -catenin, a patient-derived mutation that
has been used in many in vitro studies. As a control we
used pRosa26-DEST to knock-in lacZ into the Rosa26
locus (Figure 2a). We used transient transfection of a Cre
expression plasmid to activate the expression of the S33Y
-catenin and lacZ cDNAs (Figure 2b). Western blot anal-
ysis showed that the introduction of the att recombina-
tion sequences in the construct does not disrupt correct
expression regulation of the proteins (Figure 2c). To func-
tionally test the Rosa26-DEST-derived constructs we
measured  -catenin activity in the S33Y -catenin and
lacZ-expressing ES cells. As expected, the
Super8xTOPFlash  -catenin reporter construct [10]
showed an increased -catenin transcriptional activity in
ES cells expressing the S33Y mutation (Figure 2d). To test
whether expression of -catenin from the Rosa26 locus
results in physiologically relevant expression levels, we
quantified  -catenin expression with real-time reverse-
transcriptase polymerase chain reaction (RT-PCR). As the
mutant cDNA construct was based on the human cDNA,
we could design mouse and human -catenin specific
TaqMan assays. We confirmed the specificity of the assays
on a dilution series of both cDNA constructs (Figure 2e).
Absolute quantification of mouse (endogenous locus)
and human (Rosa26 locus) -catenin showed that the
expression level from the Rosa26 locus is approximately
half that of the endogenous -catenin locus (Figure 2f). As
the endogenous -catenin is present in two copies, while
the Rosa26 knock-in messenger is expressed from a single
copy, and in human cancer just one copy of -catenin is
activated by oncogenic mutations, we have achieved a
highly relevant expression system for mutant -catenin. As
expected, the human -catenin construct was not detected
in the control Rosa26-lacZ cells. Several cDNA constructs
generated with pRosa26-DEST, including the S33Y -cat-
enin allele, have now been passed through the germline
and are currently being analysed, the results of which will
be published elsewhere.
Cre-regulated RNAi using pRosa26-DEST
In recent years RNAi has evolved into a powerful in vitro
and in vivo technique to analyse gene function. By placing
a siRNA target sequence of choice in the backbone of an
endogenous miRNA, expression from RNA polymerase II
promoters can be achieved [11,12], enabling the use of
inducible and tissue-specific promoters in mice. Since
endogenous miRNAs are processed out of larger tran-
scripts [13], we reasoned that it should be possible to
express artificial miRNAs from the Cre-regulated Rosa26
locus (Figure 3). We used a commercially available and
Gateway-compatible miR-155-based vector and designed
a miRNA construct against Oct4. It has been shown that
this gene is essential for ES cells to maintain their undif-
ferentiated state, and loss of Oct4 in ES cells in the pres-
ence of LIF results in specific differentiation towards the
trophectoderm lineage [14], thereby providing a powerful
functional test of the efficiency of RNAi using pRosa26-
DEST. Using transient overexpression of the miRNA vec-
tor in undifferentiated ES cells (using the CMV promoter
in the miRNA vector, see Figure 3), we confirmed the
functionality of the target sequence (Figure 4a). Genera-
tion of a miRNA-expressing pRosa26-DEST construct was
found to be as efficient as the generation of cDNA con-
structs. After subcloning of the miRNA fragment into
pRosa26-DEST vector via a simple combined BP/LR reac-
tion, we targeted the constructs to MG-4 ES cells, an E14-
derived cell line that stably expresses a tamoxifen-regulat-
able Cre recombinase (Figure 4b). We activated expres-
sion of the miRNA using tamoxifen. In two independent
Oct4 knock-down clones this resulted in the appearance
of large flat, often multi-nucleated cells suggestive of tro-
phectoderm (data not shown). Quantitative RT-PCR
showed an approximately 80% reduction in Oct4 expres-
sion (see Figure 4c). Expression analysis of markers for
different differentiation lineages confirmed that the cells
were preferentially differentiated towards trophectoderm
(see Figure 4d). These results were confirmed using a cell-
permeable Cre to activate expression of the miRNA [15]
(data not shown).PathoGenetics 2008, 1:3 http://www.pathogenetics.com/content/1/1/3
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Discussion
The Rosa26-DEST vector solves a major bottleneck in the
generation of Rosa26 knock-in targeting vector construc-
tion. Its use is dependent on having the cDNA or miRNA
in a Gateway-compatible vector. In our experience the
most efficient way of cloning cDNA constructs is using a
PCR and Gateway-mediated recombination approach.
Using standard high-fidelity Taq polymerase and normal
sequencing facilities we have generated several sequence
verified clones in parallel, ready for recombination into
pRosa26-DEST in four to five days, making the total time
needed to generate constructs eight to nine days. At
present we have generated and targeted 12 cDNA con-
structs which are in different stages of analysis in ES cells
or mouse models.
By using the same vector for Cre-regulated RNAi we have
described a high-speed system that provides a potential
rapid alternative for normal conditional knock-out exper-
iments. Using the method and vectors described here
complete constructs can be made in only seven days with,
again, minimal hands-on time. The specific differentia-
tion towards trophectoderm as a result of Rosa26-medi-
ated knock-out of Oct4 shows physiological-relevant
phenotypes can be reproduced in ES cells. Its in vivo use
needs to be confirmed, for which we are currently testing
several constructs designed against disease genes where
mutations in their human counterparts result in hypo-
morphic rather than complete loss-of-function alleles
(data not shown). We believe that in many situations the
use of Rosa26-DEST-based miRNA constructs can form a
rapid alternative to conditional mouse models, while dif-
ferent target sequences against the same gene can easily
Use of pRosa26-DEST for Cre-regulated expression of cDNA constructs Figure 1
Use of pRosa26-DEST for Cre-regulated expression of cDNA constructs. Entry vectors carrying Gateway-compati-
ble cDNA constructs without any regulatory sequences can be shuttled into pRosa26-DEST using a LR reaction in which the 
ccdB bacterial negative counter-selection gene is lost. The construct is recombined via gene targeting into the endogenous 
Rosa26 locus. The first exon of the Rosa26 locus (outside the targeting construct) will splice to the splice acceptor site in the 
construct but transcription is interrupted by the PGK-neo-pA and three copies of the SV40 polyA signal, which function as a 
STOP cassette. Cre-mediated removal of this cassette links Rosa26 exon 1 to the cDNA and thus the cDNA is expressed. As 
the endogenous Rosa26 transcripts are not translated into protein, the first start codon in the cDNA will be used for initiation 
of translation. Fragments shown in green can be expressed, fragments in red cannot; the ccdB counter-selection gene in blue is 
expressed in bacteria only.
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pRosa26-DEST derived constructs are activated by expression of Cre Figure 2
pRosa26-DEST derived constructs are activated by expression of Cre. (a) Screening scheme of pRosa26-DEST tar-
geted embryonic stem (ES) clones via Southern blot. Note that the size of the detected fragment after activation of the con-
struct with Cre depends on the exact position of an EcoRV site in the cDNA in the construct; if no EcoRV is present the 11 kb 
band found in wildtype cells will become longer. (b) Southern blot confirmation of correctly targeted and activated S33Y -cat-
enin and lacZ ES clones. (c) Western blot analysis of S33Y -catenin and lacZ ES cells before and after activation of the con-
struct using transient expression of Cre. (d) -catenin activity measured as the ratio between TopFlash and FopFlash signals in 
S33Y -catenin and lacZ ES cells. (e) Demonstration of specificity of the human and murine -catenin TaqMan assays using 
absolute dilution curves of both amplification products. (f) Absolute quantification of -catenin expression from endogenous 
locus (mouse -catenin) and Rosa26 locus (human -catenin).
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provide allelic series when gene dosage effects are to be
studied [3]. The possibility of linking different miRNA tar-
gets in the same construct [12] should enable parallel
knock-down of different genes in the same mouse without
the need for time-consuming breeding schemes.
Use of the Rosa26 or any other endogenous locus is likely
to result in lower expression levels than found in conven-
tional transgenics, as these will have higher copy numbers
and often use artificial promoters selected for high expres-
sion. Our real-time RT-PCR data shows that expression
from the Rosa26 locus results in physiological relevant
expression levels, and might therefore be preferable when
the purpose of the model is to accurately mimic the situa-
tion in a human disease. In fact, use of vectors such as
pRosa26-DEST might help dissect gene-specific pheno-
types from phenotypes (partially) caused by overexpres-
sion artefacts. If the highest possible expression level is
needed, then the Multisite Gateway system should pro-
vide the possibility of including custom promoter ele-
ments, selected for high, tissue-specific or inducible
expression in pRosa26-DEST-based constructs. This
approach might also be useful for the docking of reporter
constructs into the Rosa26 locus. Preliminary experiments
show these types of constructs can indeed be made and
several constructs are currently being tested (data not
shown). Another alternative to achieve high expression of
Cre-regulatable transgenes is the CLIP vector [16]. This
vector has the additional advantage of providing positive
selection for Cre-mediated activation of the expression
cassette in ES cells; however, its random integration into
the genome has the potential to inactivate endogenous
genes.
We are currently testing different ways to further improve
the targeting efficiency in order to obtain to a system
Use of pRosa26-DEST for Cre-regulated RNAi Figure 3
Use of pRosa26-DEST for Cre-regulated RNAi. Target sequences can be cloned as double-stranded oligonucleotides 
into a Gateway-compatible miRNA vector. This vector can directly be used to test different target sequences or the miRNA 
fragment can be transferred to pRosa26-DEST via a combined BP/LR reaction. The resulting vector is ready for targeting as 
described in Figure 1. Expression of the miRNA is blocked by the lox-STOP-lox cassette. Cre-mediated removal of this cas-
sette links the miRNA to exon 1 of the endogenous Rosa26 locus to transcribe a chimeric transcript consisting of Rosa26 exon 
1 and the miRNA sequence. The miRNA will be processed out of this primary transcript by Drosha, Dicer and the RISC com-
plex and lead to knock-down of the target gene like other endogenous miRNAs.
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where we no longer need to test single ES clones for cor-
rect targeting, but can instead rely on using pools of sta-
ble, neomycin-resistant clones. Combined with the
development of cell-permeable Cre proteins [15] for test-
ing constructs in ES cells and the recently described meth-
ods for generation of fully ES-derived embryos and mice
from commonly used inbred ES lines [17], we envision a
'gene analysis pipeline' that will greatly accelerate the in
vivo functional annotation of the mouse genome.
Conclusion
The pRosa26-DEST vector provides an efficient system to
generate Cre-regulated knock-in constructs for the Rosa26
locus. It can be used for expression of cDNA and miRNA
constructs. As such, it can provide a rapid alternative for
the generation of mouse models with predictable expres-
sion patterns and levels.
Methods
Vector construction
All oligos were from Invitrogen (standard purification).
pBigT-DEST was generated by digesting pBigT [7] with
XhoI and blunted using Klenow polymerase. The C1 cas-
sette from the Gateway Conversion System (Invitrogen)
was inserted and transformed into DB3.1 bacteria (Invit-
rogen) and selected for combined Amp/Cam resistance.
Restriction digests were used to check the orientation of
the Gateway cassette. To generate pRosa26-DEST the PacI/
AscI fragment from pBigT-DEST was transferred to
pRosa26/PA [7]. pBigT and pRosa26/PA were a kind gift
Oct4 knock-down using pRosa26-DEST phenocopies the conventional knock-out phenotype Figure 4
Oct4 knock-down using pRosa26-DEST phenocopies the conventional knock-out phenotype. (a) Western blot of 
undifferentiated embryonic stem (ES) cells transiently transfected with pcDNA6.2-GW/EmGFP-miR lacZ and pcDNA6.2-GW/
EmGFP-miR Oct4. (b) Southern blot confirmation of two independent MG-4 derived ES clones targeted with the pRosa26-
miOct4 construct. The screening strategy is the same as in Figure 2a before expression of Cre. (c) Oct4 expression after 
tamoxifen treatment to activate the CreERT2 in MG-4 cells and its derivates. (d) Marker analysis of Oct-4 knock-down ES 
cells.
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from Dr Frank Costantini (Columbia University, New
York). The pRosa26-DEST vector was checked for
unwanted recombination events using PCRs for different
parts of the vector and sequencing of essential regions.
S33Y  -catenin was amplified using bcat-attB/F-myc
(GGGACAAGTTTGTACAAAAAAGCAGGCTTCACCATGG
AACAAAAACTCATCTCAGAAGAGGATCTGATGGCTACT-
CAAGCTGATTTG) and bcat-attB/R
(GGGGACCACTTTGTACAAGAAAGCTGGGTCCTACAG-
GTCAGTATCAAACCAGG). The forward primer contains
an attB1 site followed by a Kozak sequence, myc epitope
tag and 20 nt homology to the 5' end of the human -cat-
enin cDNA. The reverse primer contained 20 nt homology
to the 3' end of human -catenin, stop codon and attB2
sequences. A cDNA construct with S33Y human -catenin
(a kind gift from Dr Marc van de Wetering, Hubrecht Lab-
oratory, Utrecht) was used as a template. The fragment
was amplified using the Expand High Fidelity PCR system
(Roche) and cloned into pDONR-221 using BP clonase
enzyme mix (Invitrogen). PCR inserts were sequence ver-
ified in both orientations. The resulting vector was desig-
nated pENTR-S33 -catenin. To generate pENTR-lacZ, the
lacZ coding region from pLenti4/TO/V5-GW/lacZ was
transferred to pDONR-221 using a BP reaction. For the
final targeting vectors pRosa26-DEST was mixed with
pENTR-S33  -catenin or pENTR-lacZ in a 6-hour LR
recombination reaction using LR clonase enzyme mix
(Invitrogen), followed by transformation into Stbl3 E. coli
cells and grown at 30°C. For each construct 16 clones
were miniprepped and several correct clones were identi-
fied for each based on PacI/AscI digest and KpnI digest.
miRNA targets against Oct4 were designed using the
BLOCK-iT RNAi designer [18]. Oligos Oct4-846-TOP
(TGCTGTACAGAACCATACTCGAACCAGTTTTGGCCAC
TGACTGACTGGTTCGAATGGTTCTGTA) and Oct4-846-
BOT
(CCTGTACAGAACCATTCGAACCAGTCAGTCAGTGGCC
AAAACTGGTTCGAGTATGGTTCTGTAC) were cloned
into pcDNA6.2-GW/EmGFP-miR (Invitrogen) according
to the supplier's instructions. The supplied miLacZ oligos
were used to generate a control miRNA construct against
lacZ. Inserted oligos were sequence verified using the sup-
plied sequencing primers. The Oct4 miRNA vector was
mixed with pDONR-221 for a 6-hour BP reaction, imme-
diately followed by an overnight LR reaction with
pRosa26-DEST as recipient vector and transformed into
Stbl3 cells. Again several correct clones could be identified
based on PacI/AscI and KpnI digestions of 16 miniprepped
clones. The resulting construct was designated pRosa26-
miOct4-846.
All targeting vectors were maxiprepped using Qiagen Plas-
mid Maxi kit and 100 g vector was linearized with KpnI.
Digestions were ethanol precipitated overnight at -20°C,
spun down, air-dried in a cell culture flow cabinet, dis-
solved in phosphate buffered saline (PBS) and used for
electroporation of ES cells.
ES cell culture
E14IVtg2a cells (107) were grown on feeder-free gelati-
nized plates in LIF-supplemented medium and electropo-
rated with 100 g linearized (KpnI) targeting vector and
selected for 9 to 10 days in G418 (250 g/ml). Single
clones were picked, expanded, frozen and tested for cor-
rect targeting using Southern blot as described previously
[7].
MG-4 cells were derived from E14IVtg2a cells by electro-
porating them with 100 g of a CAGGs-CreERT2-IRES-
puro construct (a kind gift from Dr Lars Grotewold, ISCR,
University of Edinburgh) and selection on puromycin
(Invivogen, final concentration 1 g/ml). Several inde-
pendent puromycin-resistant clones were tested and
shown to express CreERT2 using Western blot analysis.
One clone, MG-4, was shown to give germline transmis-
sion after generation of chimeric mice. MG-4 cells were
electroporated with the pRosa26-miOct4-846 construct as
described above.
4-OH Tamoxifen (Sigma) was dissolved in ethanol to 1
mg/ml (1000 × final concentration) and stored at -20°C.
For activation of Cre in MG-4-derived cells, 7.5 × 106 cells
were grown overnight in T75 flasks in normal ES medium.
The next day 4-OH Tamoxifen or ethanol for controls was
added and cells were grown for an additional three days
with daily medium changes. Finally the cells were grown
for another three days in normal ES medium without 4-
OH Tamoxifen or ethanol.
Western blot analysis
Lysates were made using Complete Lysis-M (Roche) and
50 g was run on sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) minigels. Antibodies
were 9E10 (Santa Cruz, recognizing the myc epitope on
S33Y -catenin), C10 (Santa Cruz sc-5279, recognizing
Oct3/4), CR7001RPZ (Cortex, recognizing lacZ) and
AB407 (Autogen Bioclear, recognizing PCNA as the load-
ing control).
-catenin activity assay
8xSuperTOPFlash and 8xSuperFOPFlash (kind gifts from
Dr Randall Moon, Howard Hughes Medical Institute,
University of Washington) [10] were used to measure -
catenin activity. ES cells were plated in 96 well plates at a
density of 12500 cells per well and grown overnight. Cells
were transfected overnight with 62.5 ng 8xTOPFlash or
8xFOPFlash construct, 62.5 ng pRL-TK (Promega) and
0.3125 l Lipofectamine-2000 (Invitrogen) per well. Luci-PathoGenetics 2008, 1:3 http://www.pathogenetics.com/content/1/1/3
Page 9 of 10
(page number not for citation purposes)
ferase was measured using the Dual-Luciferase Reporter
Assay System (Promega).
Real-time PCR
RNA was isolated using the RNeasy mini kit (Qiagen)
with DNAse treatment on the column. Five micrograms
total RNA was transcribed with AMV (Avian Myeloblasto-
sis Virus) reverse transcriptase (Roche) and oligo(dT)
priming. All quantitative PCR assays were performed on
an ABI 7900 HT real-time PCR system with FastStart Taq-
Man Master (Rox) (Roche). Assays were performed with
the Universal Probe Library (Roche) with the primer/
probe combinations shown in Table 1. Cdx2 was meas-
ured against a standard curve of cDNA derived from
embryoid bodies grown for 10 days; Oct4, Gata4, Fgf5,
Brachyury and Hand1 were measured against a standard
curve from embryoid bodies grown for six days. For abso-
lute quantification cDNA fragments containing the real-
time PCR fragments of -actin, human -catenin and
murine -catenin were cloned in pGemT-easy (Promega),
sequence verified, diluted to exact copy numbers and used
as standard curve.
A VectorNTI archive file (additional file 1), sequence
(additional file 2), map (additional file 3) of pRosa26-
DEST and detailed protocols (additional file 4) are availa-
ble as supplementary information to this paper. For rea-
gent requests, please see [19].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PH designed the study, generated constructs, performed
ES experiments and wrote the manuscript. JS performed
ES experiments and protein analysis. DDO generated con-
structs and performed real-time PCR. SFB and RB gener-
ated constructs. NDH assisted in the design of the study
and helped in drafting the manuscript. All authors read
and approved the final manuscript.
Additional material
Acknowledgements
The authors would like to thank Frank Costantini, Marc van de Wetering, 
Lars Grotewold and Randall Moon for reagents and Agnes Gallacher and 
Stephen Brown for technical assistance. PH was supported by the Associa-
tion of International Cancer Research, SFB by Kidney Research UK and RB 
by EuReGene, a framework 6 program grant by the European Commission 
(05085).
References
1. Kunath T, Gish G, Lickert H, Jones N, Pawson T, Rossant J: Trans-
genic RNA interference in ES cell-derived embryos recapit-
ulates a genetic null phenotype.  Nat Biotechnol 2003,
21:559-561.
2. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs
L, Jaenisch R, Jacks T: Cre-lox-regulated conditional RNA inter-
ference from transgenes.  Proc Natl Acad Sci USA 2004,
101:10380-10385.
3. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-
Cardo C, Hannon GJ, Lowe SW: An epi-allelic series of p53 hypo-
Table 1: Primers and UPL probes used in the real-time reverse-transcriptase polymerase chain reaction experiments
Transcript Forward Reverse Probe
Oct4 GTTGGAGAAGGTGGAACCAA CTCCTTCTGCAGGGCTTTC 95
-actin AAGGCCAACCGTGAAAAGAT GTGGTACGACCAGAGGCATAC 56
Gata4 GGAAGACACCCCAATCTCG CATGGCCCCACAATTGAC 13
Fgf5 AAAACCTGGTGCACCCTAGA CATCACATTCCCGAATTAAGC 29
Brachyury CGACCACAAAGATGTAATGGAG CCAGCACCAGGAACAAGC 66
Hand1 AGCGGAAAAGGGAGTTGC GCGCCCTTTAATCCTCTTCT 51
Cdx2 CTGCCACACTTGGGCTCT CTTGGCTCTGCGGTTCTG 34
Human -catenin GCAGAGTGCTGAAGGTGCTA TCTGTCAGGTGAAGTCCTAAAGC 31
Mouse -catenin ATGAAGGCGTGGCAACATAC TGTGGCTTGTCCTCAGACAT 56
Additional file 1
VectorNTI archive file for pRoas26-DEST.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8417-1-3-S1.ma4]
Additional file 2
pRosa26-DEST sequence in genbank format.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8417-1-3-S2.txt]
Additional file 3
pRosa26-DEST map.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8417-1-3-S3.pdf]
Additional file 4
pRosa26-DEST information file including protocols.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1755-
8417-1-3-S4.pdf]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
PathoGenetics 2008, 1:3 http://www.pathogenetics.com/content/1/1/3
Page 10 of 10
(page number not for citation purposes)
morphs created by stable RNAi produces distinct tumor
phenotypes in vivo.  Nat Genet 2003, 33:396-400.
4. Friedrich G, Soriano P: Promoter traps in embryonic stem cells:
a genetic screen to identify and mutate developmental genes
in mice.  Genes Dev 1991, 5:1513-1523.
5. Zambrowicz BP, Imamoto A, Fiering S, Herzenberg LA, Kerr WG,
Soriano P: Disruption of overlapping transcripts in the ROSA
beta geo 26 gene trap strain leads to widespread expression
of beta-galactosidase in mouse embryos and hematopoietic
cells.  Proc Natl Acad Sci USA 1997, 94:3789-3794.
6. Soriano P: Generalized lacZ expression with the ROSA26 Cre
reporter strain.  Nat Genet 1999, 21:70-71.
7. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM,
Costantini F: Cre reporter strains produced by targeted inser-
tion of EYFP and ECFP into the ROSA26 locus.  BMC Dev Biol
2001, 1:4.
8. Hartley JL, Temple GF, Brasch MA: DNA cloning using in vitro
site-specific recombination.  Genome Res 2000, 10:1788-1795.
9. Kielman MF, Rindapaa M, Gaspar C, van Poppel N, Breukel C, van
Leeuwen S, Taketo MM, Roberts S, Smits R, Fodde R: Apc modu-
lates embryonic stem-cell differentiation by controlling the
dosage of beta-catenin signaling.  Nat Genet 2002, 32:594-605.
10. Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT: Zebrafish
prickle, a modulator of noncanonical Wnt/Fz signaling, reg-
ulates gastrulation movements.  Curr Biol 2003, 13:680-685.
11. Zeng Y, Wagner EJ, Cullen BR: Both natural and designed micro
RNAs can inhibit the expression of cognate mRNAs when
expressed in human cells.  Mol Cell 2002, 9:1327-1333.
12. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, Vojtek
AB, Turner DL: Polycistronic RNA polymerase II expression
vectors for RNA interference based on BIC/miR-155.  Nucleic
Acids Res 2006, 34:e53.
13. Cullen BR: RNAi the natural way.  Nat Genet 2005, 37:1163-1165.
14. Niwa H, Miyazaki J, Smith AG: Quantitative expression of Oct-3/
4 defines differentiation, dedifferentiation or self-renewal of
ES cells.  Nat Genet 2000, 24:372-376.
15. Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F: Ability of the
hydrophobic FGF and basic TAT peptides to promote cellu-
lar uptake of recombinant Cre recombinase: a tool for effi-
cient genetic engineering of mammalian genomes.  Proc Natl
Acad Sci USA 2002, 99:4489-4494.
16. George SH, Gertsenstein M, Vintersten K, Korets-Smith E, Murphy J,
Stevens ME, Haigh JJ, Nagy A: Developmental and adult pheno-
typing directly from mutant embryonic stem cells.  Proc Natl
Acad Sci USA 2007, 104:4455-4460.
17. Poueymirou WT, Auerbach W, Frendewey D, Hickey JF, Escaravage
JM, Esau L, Doré AT, Stevens S, Adams NC, Dominguez MG, Gale
NW, Yancopoulos GD, DeChiara TM, Valenzuela DM: F0 genera-
tion mice fully derived from gene-targeted embryonic stem
cells allowing immediate phenotypic analyses.  Nat Biotechnol
2007, 25:91-99.
18. BLOCK-iT RNAi designer   [https://rnaidesigner.invitrogen.com/
rnaiexpress/]
19. Professor Nick Hastie's Research Page at the Human Genet-
ics Unit of the Medical Research Council   [ h t t p : / /
www.hgu.mrc.ac.uk/Research/Hastie/home.html]